

Alnylam Act® Primary Hyperoxaluria Type 1 (45 genes)
The Alnylam Act® program offers complimentary 45-gene panel testing and genetic counseling for patients with suspected PH1 or a relevant family history (covering AGXT, GRHPR, HOGA1 and additional nephrolithiasis-associated genes). This expanded panel aids you in distinguishing PH1 from related conditions, supporting diagnosis, management pathways and family screening. All services are provided at no charge to the patient, provider or payer.